Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Debt (2022 - 2024)

Historic Non-Current Debt for Summit Therapeutics (SMMT) over the last 3 years, with Q1 2024 value amounting to $100.0 million.

  • Summit Therapeutics' Non-Current Debt changed 0.0% to $100.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $100.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $100.0 million for FY2023, which is 7977.92% down from last year.
  • Summit Therapeutics' Non-Current Debt amounted to $100.0 million in Q1 2024, which was down 0.0% from $100.0 million recorded in Q4 2023.
  • Over the past 5 years, Summit Therapeutics' Non-Current Debt peaked at $494.5 million during Q4 2022, and registered a low of $25.1 million during Q1 2022.
  • Over the past 3 years, Summit Therapeutics' median Non-Current Debt value was $100.0 million (recorded in 2023), while the average stood at $135.0 million.
  • Within the past 5 years, the most significant YoY rise in Summit Therapeutics' Non-Current Debt was 29912.19% (2023), while the steepest drop was 7977.92% (2023).
  • Over the past 3 years, Summit Therapeutics' Non-Current Debt (Quarter) stood at $494.5 million in 2022, then crashed by 79.78% to $100.0 million in 2023, then changed by 0.0% to $100.0 million in 2024.
  • Its Non-Current Debt was $100.0 million in Q1 2024, compared to $100.0 million in Q4 2023 and $100.0 million in Q2 2023.